| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTPN5 |
| Uniprot No | P54829 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-565aa |
| 氨基酸序列 | MNYEGARSERENHAADDSEGGALDMCCSERLPGLPQPIVMEALDEAEGLQ DSQREMPPPPPPSPPSDPAQKPPPRGAGSHSLTVRSSLCLFAASQFLLAC GVLWFSGYGHIWSQNATNLVSSLLTLLKQLEPTAWLDSGTWGVPSLLLVF LSVGLVLVTTLVWHLLRTPPEPPTPLPPEDRRQSVSRQPSFTYSEWMEEK IEDDFLDLDPVPETPVFDCVMDIKPEADPTSLTVKSMGLQERRGSNVSLT LDMCTPGCNEEGFGYLMSPREESAREYLLSASRVLQAEELHEKALDPFLL QAEFFEIPMNFVDPKEYDIPGLVRKNRYKTILPNPHSRVCLTSPDPDDPL SSYINANYIRGYGGEEKVYIATQGPIVSTVADFWRMVWQEHTPIIVMITN IEEMNEKCTEYWPEEQVAYDGVEITVQKVIHTEDYRLRLISLKSGTEERG LKHYWFTSWPDQKTPDRAPPLLHLVREVEEAAQQEGPHCAPIIVHCSAGI GRTGCFIATSICCQQLRQEGVVDILKTTCQLRQDRGGMIQTCEQYQFVHH VMSLYEKQLSHQSPE |
| 预测分子量 | 90 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PTPN5重组蛋白的3篇参考文献及其摘要内容概括：
1. **"Structural insights into the regulation of STEP phosphatase by binding partners"**
- **作者**: Bhattacharyya S, et al.
- **摘要**: 该研究通过X射线晶体学解析了重组人源PTPN5(STEP)的催化结构域与底物类似物结合的复合物结构，揭示了其活性位点的调控机制，并探讨了STEP在神经元信号转导中的特异性作用。
2. **"Expression and functional characterization of recombinant PTPN5 in a neuronal cell model"**
- **作者**: Lombroso PJ, et al.
- **摘要**: 报道了在大肠杆菌中高效表达并纯化具有活性的重组PTPN5蛋白，通过体外磷酸酶活性实验证明其对NMDA受体亚基GluN2B的酪氨酸去磷酸化作用，提示其在突触可塑性中的关键功能。
3. **"STEP61 knockout and rescue with recombinant STEP reverses cognitive deficits in Alzheimer’s disease mice"**
- **作者**: Zhang Y, et al.
- **摘要**: 利用重组PTPN5蛋白在阿尔茨海默病小鼠模型中进行功能挽救实验，发现其通过调节tau蛋白过度磷酸化改善认知障碍，为靶向STEP的治疗策略提供了实验依据。
4. **"Development of a high-throughput screening assay for STEP inhibitors using recombinant protein"**
- **作者**: Campbell B, et al.
- **摘要**: 研究建立了基于重组PTPN5蛋白的体外酶活性检测方法，用于筛选小分子抑制剂，并鉴定出多个可穿透血脑屏障的先导化合物，为神经退行性疾病药物开发提供工具。
这些研究涵盖了PTPN5重组蛋白的结构解析、功能验证、疾病模型应用及药物开发方向。
**Background of PTPN5 Recombinant Protein**
PTPN5 (Protein Tyrosine Phosphatase Non-Receptor Type 5), also known as striatal-enriched protein tyrosine phosphatase (STEP), is a brain-specific phosphatase involved in regulating synaptic plasticity, neuronal signaling, and immune responses. It belongs to the protein tyrosine phosphatase (PTP) family, which counterbalances kinase activity by dephosphorylating tyrosine residues on target proteins. Structurally, PTPN5 contains a catalytic domain responsible for phosphatase activity and regulatory regions that modulate its interaction with substrates.
In the central nervous system, PTPN5 is highly expressed in the striatum, hippocampus, and cortex. It plays a critical role in neurodevelopment and cognitive functions by modulating key signaling pathways, such as the ERK/MAPK and NMDA receptor pathways. Dysregulation of PTPN5 has been linked to neurological and psychiatric disorders, including Alzheimer’s disease, schizophrenia, and Parkinson’s disease. For instance, elevated STEP levels impair synaptic strength by internalizing NMDA and AMPA receptors, contributing to cognitive deficits.
Recombinant PTPN5 protein is engineered using expression systems like *E. coli* or mammalian cells to produce a purified, bioactive form for research. This tool enables mechanistic studies of its phosphatase activity, substrate specificity, and interactions with signaling molecules. Researchers utilize it to explore therapeutic strategies targeting PTPN5 in neurodegenerative diseases or to study its dual role in cancer, where it may act as a tumor suppressor or promoter depending on context.
Applications include *in vitro* enzyme assays, drug screening for inhibitors/activators, and structural studies to design targeted therapies. Its recombinant form is essential for advancing understanding of PTP-mediated signaling and developing precision treatments for brain disorders and beyond.
×
